Report Detail
Colitis - Pipeline Review, H2 2019
- RnM3784274 |
- 26 September, 2019 |
- Global |
- 120 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Colitis - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.
Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Unknown stages are 1, 2, 26 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.
Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colitis - Overview
Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Colitis - Companies Involved in Therapeutics Development
AlfaSigma SpA
Apollo Endosurgery Inc
Concenter BioPharma Silkim Ltd
enGene Inc
Genfit SA
Handa Pharmaceuticals LLC
Immodulon Therapeutics Ltd
Immuron Ltd
Inflazome Ltd
Nippon Kayaku Co Ltd
Principia Biopharma Inc
Protagonist Therapeutics Inc
RDD Pharma Ltd
Scholar Rock Inc
Soligenix Inc
Symbiotix Biotherapies Inc
Synthetic Biologics Inc
Vitality Biopharma Inc
Colitis - Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Colitis and Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAK-11049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Colitis, Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit LTC4 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito Urinary System and Sex Hormones Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-1140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Colitis and Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Androgen Receptor and Glucocorticoid Receptor for Oncology, Autoimmune diseases and Inflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Colitis and Crohn's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Gastrointestinal, Hematological Disorders, Immunology, Metabolic Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYMB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYMB-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPC-1022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
May 10, 2018: Vitality's GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections
May 07, 2018: Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis
Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis
Jul 19, 2017: Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease
Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Colitis. Industry analysis & Market Report on Colitis is a syndicated market report, published as Colitis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Colitis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
